Pulvisonide 200

Pulvisonide 200



T. O. Chemicals


T. O. Chemicals
Concise Prescribing Info
Dosage/Direction for Use
Adult 200 to >800 mcg daily in 2-4 divided doses. May be increased to 1,600 mcg in more severe cases. Full dose up to 400 mcg/day may be given in 1 administration. Childn 6-11 yr 100 to >400 mcg daily in 2-4 divided doses. Full daily dose may be given in 1 administration.
Hypersensitivity. Primary treatment of status asthmaticus & acute episode of asthma. Not to be used to relieve acute bronchospasm.
Special Precautions
Thyroid disease, CV disease, diabetics, glaucoma, cataracts & myasthenia gravis; acute MI. Patients at risk for osteoporosis, seizures & GI diseases (eg, diverticulitis, peptic ulcer, ulcerative colitis). Discontinue treatment if bronchospasm occurs & immediately treat w/ a short-acting inhaled bronchodilator. Patients switching from oral systemic to orally inhaled corticosteroid. Monitor growth of childn & adolescents in prolonged use. Hepatic impairment.
Adverse Reactions
Rhinitis, upper resp tract infections; otitis media. Eczema, pruritus, rash; abdominal pain, anorexia, diarrhea, gastroenteritis, nausea, vomiting, oral candidiasis; coughing, dysphonia, nasal congestion, pharyngitis, chest pain; conjunctivitis; ear infection, earache; infection, flu-like syndrome.
Drug Interactions
Increased plasma conc w/ CYP3A4 inhibitors eg, ketoconazole, itraconazole. Decreased plasma conc w/ CYP3A4 inducers. Aldesleukin, loxapine.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03BA02 - budesonide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
Pulvisonide 200 inhalation powd cap
20 × 5's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in